Michael Brundage
Overview
Explore the profile of Michael Brundage including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
3064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alghamdi S, Ahimsadasan N, Kong W, Brundage M, Eisenhauer E, Parker C, et al.
Curr Oncol
. 2024 Oct;
31(10):6073-6084.
PMID: 39451757
(1) Background: Comprehensive and timely lung cancer (LC) staging is essential for prognosis and management. The Lung Diagnostic Assessment Program (LDAP) in Southeastern (SE) Ontario aims to provide rapid, guideline-concordant...
2.
Schuster A, Crossnohere N, Adjei Boakye E, Angove R, Baldwin B, Barreto E, et al.
Patient
. 2024 Jun;
18(1):89-95.
PMID: 38909128
No abstract available.
3.
Integrating Patient-Reported Outcomes Into the Care of People With Advanced Cancer-A Practical Guide
Lai-Kwon J, Thorner E, Rutherford C, Crossnohere N, Brundage M
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e438512.
PMID: 38788184
Patient-reported outcomes (PROs) are being increasingly integrated into routine clinical practice to enhance individual patient care. This has been driven by recognition of the benefits of PROs in enhancing symptom...
4.
Crossnohere N, Anderson N, Baumhauer J, Calvert M, Esparza R, Gulbransen S, et al.
Nat Med
. 2024 Apr;
30(6):1519-1520.
PMID: 38627558
No abstract available.
5.
Aiyegbusi O, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y, Anderson N, et al.
Nat Med
. 2024 Feb;
30(3):650-659.
PMID: 38424214
Patient-reported outcomes (PROs) are increasingly used in healthcare research to provide evidence of the benefits and risks of interventions from the patient perspective and to inform regulatory decisions and health...
6.
Ashworth A, Kong W, Owen T, Hanna T, Brundage M
Radiother Oncol
. 2024 Feb;
194:110153.
PMID: 38364940
Background: Stereotactic Ablative Body Radiotherapy (SABR) is the standard of care for medically inoperable patients with Stage I NSCLC. The adoption of SABR and its association with cancer outcomes requires...
7.
Kerba M, De Abreu Lourenco R, Sahgal A, Cardet R, Siva S, Ding K, et al.
Int J Radiat Oncol Biol Phys
. 2024 Jan;
119(4):1061-1068.
PMID: 38218455
Purpose: The Canadian Cancer Trials Group (CCTG) Symptom Control 24 protocol (SC.24) was a multicenter randomized controlled phase 2/3 trial conducted in Canada and Australia. Patients with painful spinal metastases...
8.
Mathews J, Merchant S, Galica J, Palmer M, ODonnell J, Koven R, et al.
J Natl Cancer Inst
. 2023 Dec;
116(4):506-517.
PMID: 38134429
Background: Assessment of prognostic awareness (PA) in patients with advanced cancer is challenging because patient responses often indicate their hopes. The objectives of this scoping review were to summarize studies...
9.
Apostolovski S, McCallum F, Simniceanu C, Kraus J, Gutierrez E, Liszewski B, et al.
Healthc Q
. 2023 Aug;
26(2):37-42.
PMID: 37572070
In 2021, Ontario Health (Cancer Care Ontario) introduced a quality-based procedure model for the funding of radiation treatment (RT) in Ontario. This model ties reimbursement to patient care activities, ensuring...
10.
Loewen S, Ruan Y, David Wu C, Arifin A, Kim M, Bashir B, et al.
Int J Radiat Oncol Biol Phys
. 2023 Aug;
119(3):756-770.
PMID: 37562734
Purpose: The number of Canadians diagnosed with cancer, and subsequent demand for radiation therapy, are expected to increase over time. This study aimed to update our needs-based workforce planning model...